# Cardinal Health: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Cardinal Health, Inc. · NYSE: CAH · Sector: Health Care

Updated for Q1 FY2027 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/cardinal-health. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Cardinal Health: how the business works", with the page URL.

## The 30-second summary

Cardinal Health buys medicines from drug makers and delivers them to US pharmacies, hospitals and clinics, with revenue of $254.2 billion in FY2026. Almost all of that money goes on the products it resells, so it kept about 67 cents of net income per $100 of revenue. CVS Health was 28% of FY2026 revenue, and in November 2026 the two signed a binding letter of intent to renew their drug distribution agreements.

## 5 points

- **What it sells:** Cardinal Health distributes branded, generic and specialty medicines to US pharmacies, hospitals and clinics, and makes its own medical products such as gloves and syringes, with revenue of $254.2 billion in FY2026. [S2]
- **Who pays it:** CVS Health paid 28% of Cardinal Health's FY2026 revenue, the next four largest customers 15% together and all other pharmacies, hospitals, clinics and patients 57% (Cityfort calculation from FY2026 10-K). [S2]
- **What it keeps from $100:** Of every $100 that came in during FY2026, Cardinal Health kept $0.7 as net income, after a $122 million write-down of its Outcomes stake and including a one-time $100 million tariff refund benefit; operating earnings were $2,613 million. [S2, S15]
- **Where the operating profit comes from:** In FY2026, Pharmaceutical and Specialty Solutions earned $2,783 million of segment profit, the other businesses (nuclear, at-home and logistics) $707 million and Global Medical Products and Distribution $258 million. [S2]
- **The one thing to watch:** CVS Health was 28% of Cardinal Health's FY2026 revenue, and on Nov 5, 2026 the company said it had signed a binding letter of intent to renew its drug distribution agreements with CVS Health. [S2, S14]

## What does Cardinal Health sell?

Cardinal Health is a middleman for medicines. It buys drugs from manufacturers, stores them in its warehouses and delivers them to pharmacies, hospitals and clinics across the US. It also makes and sells its own medical supplies, such as gloves and syringes.

- **Drug distribution:** Delivers branded, generic and over-the-counter medicines to drugstore chains, independent pharmacies, supermarket pharmacies and hospitals in the US. [S2]
- **Specialty drugs and doctor networks:** Distributes cancer, gastroenterology, urology and other specialty drugs, and runs management services for physician practices through The Specialty Alliance and Navista. [S2]
- **Cardinal Health brand medical products:** Makes or sources its own exam and surgical gloves, needles and syringes, wound-care and incontinence products, and surgical drapes and gowns. It also distributes other brands to hospitals. [S2]
- **Nuclear pharmacies:** Prepares and delivers radioactive drugs used in nuclear imaging and cancer treatment for hospitals and doctors. [S2]
- **At-home supplies:** Ships diabetes and other medical supplies straight to patients with chronic conditions, through Edgepark and ADS. [S2]
- **OptiFreight Logistics:** Manages shipping for hospitals, pharmacies, labs and surgery centers. [S2]

## Who pays Cardinal Health?

- **CVS Health (28.0% of revenue):** The drugstore and pharmacy-benefit group is the largest customer. The two companies also run Red Oak Sourcing, which buys generic drugs for both through June 2029. [S2]
- **Pharmacies:** Drugstore chains, independent pharmacies and the pharmacy counters of supermarkets and mass merchandisers buy medicines. [S2]
- **Hospitals and health systems:** Many buy through group purchasing organizations. Members of the two largest, Vizient and Premier, made up 29% of FY2026 revenue. [S2]
- **Doctors, clinics and labs:** Physician offices, surgery centers and clinical labs buy specialty drugs, medical products and practice management services. [S2]
- **Patients at home:** People with diabetes and other chronic conditions get supplies shipped to their homes. [S2]
- **Drug manufacturers:** Pay fees for distribution, inventory, data and product-launch services, usually a percentage of the list price they set. [S2]
- **Customer concentration:** largest customer 28.0%, top 5 43.0% of revenue. CVS Health was 28% of FY2026 revenue and the five largest customers were 43%, per the FY2026 10-K. OptumRx, 17% of FY2024 revenue, stopped buying when its contracts ended in June 2024. [S2, S9]

## Where the money went (FY2026)

1. Pharmacies, hospitals, clinics and patients paid Cardinal Health $254.2 billion in FY2026, the year to Jun 30, 2026.
2. Buying the drugs and products it resold or made took $244.5 billion. That left a gross margin of $9.8 billion.
3. Warehouses, delivery, staff and offices took $6.1 billion. Deal costs, write-downs and restructuring took $1.2 billion more.
4. Interest took $348 million and income tax took $469 million. Other income and minority owners added $40 million.
5. Net income for Cardinal Health shareholders was $1,714 million, up from $1,561 million in FY2025.

Sources: S2.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends June 30 (FY2026 ran from July 2025 to June 2026). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2022 (restated) | 181,364 | 85 | 0.0% | −938 | −0.5% | −3.37 | 3,175 | 387 | 2,788 | S13, S9 |
| FY2023 (restated) | 205,012 | 1,444 | 0.7% | 330 | 0.2% | 1.26 | 2,844 | 481 | 2,363 | S12, S5 |
| FY2024 | 226,827 | 1,953 | 0.9% | 852 | 0.4% | 3.45 | 3,762 | 511 | 3,251 | S9 |
| FY2025 | 222,578 | 3,065 | 1.4% | 1,561 | 0.7% | 6.45 | 2,397 | 547 | 1,850 | S5 |
| FY2026 | 254,248 | 3,569 | 1.4% | 1,714 | 0.7% | 7.23 | 5,174 | 649 | 4,525 | S2 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

At Sep 30, 2026, debt of $8.8 billion exceeded cash of $5.3 billion by $3.6 billion (Cityfort calculation from Q1 FY2027 10-Q). Shareholders’ equity was negative, a deficit of $2.9 billion, so debt-to-equity is not shown. [S1, S2, S9, S21]

| Item | Value |
| --- | --- |
| Total debt | 8,815 |
| Cash and investments | 5,264 |
| Net debt (debt minus cash) | 3,551 |
| Net worth (shareholders' money) | −2,866 |

- Debt is mostly notes and debentures (types of bonds) plus a term loan; current debt was $1,886 million and long-term debt $6,929 million at Sep 30, 2026.
- On Aug 7, 2026, a $4.0 billion revolving credit line running to August 2031 replaced its earlier bank lines and receivables facility. It limits net leverage to 4.00 times.
- It also had $4.3 billion accrued for opioid settlements at Jun 30, 2026, mostly paid out through 2038. That liability is not counted as debt here.
- Goodwill and other intangibles were $13.6 billion at Jun 30, 2026, up from $6.5 billion two years earlier, after its acquisitions.

## Who owns Cardinal Health? (as of Sep 14, 2026)

Cardinal Health has one class of common shares, one vote each, and no controlling holder. Its 17 directors and executive officers held 277,425 shares, about 0.12% (Cityfort calculation from 2026 proxy statement). [S20, S1]

- Officers and directors (as a group), shares: 0.12%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common shares (Shares outstanding on Oct 31, 2026 (10-Q cover). On the proxy record date of Sep 14, 2026, there were 231.56 million.) | 231.14 | 1 | — | — | Yes | S1, S20 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| Vanguard Capital Management | 7.6% | — | Apr 29, 2026 | From the 2026 proxy, using a Schedule 13G filed Apr 29, 2026: 17,635,857 shares. | S20 |
| Wellington Management Group LLP | 6.4% | — | Sep 14, 2026 | From the 2026 proxy: 14,860,271 shares. | S20 |
| State Street Corporation | 6.3% | — | Jan 30, 2024 | From the 2026 proxy, using a Schedule 13G/A filed Jan 30, 2024: 14,540,655 shares. | S20 |
| Vanguard Portfolio Management LLC | 6.0% | — | Apr 29, 2026 | From the 2026 proxy, using a Schedule 13G filed Apr 29, 2026: 13,786,683 shares. It is separate from the Vanguard Capital Management row. | S20 |

## What could go wrong

### Reliance on CVS Health

CVS Health was 28% of FY2026 revenue and 22% of trade receivables at Jun 30, 2026. A binding letter of intent to renew its contracts was signed in November 2026. [S2, S14]

What to watch: Whether final CVS Health agreements are signed, and their term.

### Opioid litigation

About 56 private-plaintiff suits, including about 9 purported class actions, were pending at Sep 30, 2026. Settlement payments run mostly through 2038, against $3.9 billion accrued. [S1, S2]

What to watch: The opioid accrual and payments in each 10-Q.

### Thin margins

It kept about 67 cents of net income per $100 of revenue in FY2026. Generic drug prices tend to fall after launch, and small price changes move profit. [S2]

What to watch: Gross margin per $100 of revenue in the FY2027 10-K.

### Tariffs on generic drugs

The 10-K quotes a presidential statement that generic drugs will face 100% tariffs from 2028 and 200% from 2029. The company says there is significant uncertainty about how it will be implemented. [S2, S1]

What to watch: Any tariff rule on generic drugs and what the company says about cost pass-through.

### Large acquisitions

ION, GI Alliance, ADS, Urology America and Solaris Health cost about $7.2 billion from December 2024 to November 2025 (Cityfort calculation from FY2026 10-K). In Q3 FY2026 it took a $184 million goodwill impairment on Navista and ION. [S2, S23]

What to watch: Further goodwill impairments and Pharma segment profit growth.

### Supplier and payables timing

It owed suppliers $38.3 billion at Jun 30, 2026. The 10-K says FY2026 operating cash flow reflected the timing of payments to vendors, so cash flow can swing. [S2]

What to watch: Operating cash flow and accounts payable in each 10-Q.

## What to watch

Next: Q2 FY2027 results, Date not announced yet.

- **Final CVS Health agreements:** The binding letter of intent was signed in November 2026; CVS Health was 28% of FY2026 revenue, and Red Oak Sourcing runs through June 2029.
- **The FY2027 outlook:** On Nov 5, 2026, management raised its FY2027 non-GAAP EPS outlook to $12.80 to $13.00; Q1 FY2027 non-GAAP EPS was $3.26.
- **Medical products profit:** Global Medical Products and Distribution (GMPD) earned $258 million in FY2026, including a one-time $100 million tariff refund benefit, and $33 million in Q1 FY2027, down from $46 million.
- **Tariffs on generic drugs:** The FY2026 10-K quotes a presidential statement of 100% tariffs on generic drugs from 2028 and 200% from 2029; the company says there is significant uncertainty about how they will be implemented.

## Sources

- S1: Form 10-Q for Q1 FY2027. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000043/0000721371-26-000043-index.htm (published Nov 5, 2026)
- S2: Form 10-K for FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000038/0000721371-26-000038-index.htm (published Aug 11, 2026)
- S3: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/0000721371-26-000006-index.htm (published Feb 5, 2026)
- S4: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137125000130/0000721371-25-000130-index.htm (published Oct 30, 2025)
- S5: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/0000721371-25-000079-index.htm (published Aug 12, 2025)
- S6: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137125000038/0000721371-25-000038-index.htm (published May 1, 2025)
- S7: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137125000013/0000721371-25-000013-index.htm (published Jan 30, 2025)
- S8: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137124000121/0000721371-24-000121-index.htm (published Nov 1, 2024)
- S9: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137124000056/0000721371-24-000056-index.htm (published Aug 14, 2024)
- S10: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137124000038/0000721371-24-000038-index.htm (published May 2, 2024)
- S11: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000162828024002813/0001628280-24-002813-index.htm (published Feb 1, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137123000060/0000721371-23-000060-index.htm (published Aug 15, 2023)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137122000058/0000721371-22-000058-index.htm (published Aug 11, 2022)
- S14: Q1 FY2027 earnings release (8-K Ex. 99.1, filed Nov 5, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000042/a27q1_x093026xex991xnewsre.htm (published Nov 5, 2026)
- S15: Q4 FY2026 earnings release (8-K Ex. 99.1, filed Aug 11, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000037/a26q4_x063026xex991xnewsre.htm (published Aug 11, 2026)
- S16: Q3 FY2026 earnings release (8-K Ex. 99.1, filed Apr 30, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000017/a26q3_x033126xex991xnewsre.htm (published Apr 30, 2026)
- S17: Q2 FY2026 earnings release (8-K Ex. 99.1, filed Feb 5, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000004/a26q2_x123125xex991xnewsre.htm (published Feb 5, 2026)
- S18: Q1 FY2026 earnings release (8-K Ex. 99.1, filed Oct 30, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm (published Oct 30, 2025)
- S19: Q4 FY2025 earnings release (8-K Ex. 99.1, filed Aug 12, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137125000075/a25q4_x063025xex991xnewsre.htm (published Aug 12, 2025)
- S20: 2026 proxy statement (DEF 14A, filed Sep 21, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000130817926000402/cah-20260921.htm (published Sep 21, 2026)
- S21: 8-K filed Aug 11, 2026: $4.0 billion revolving credit agreement. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000036/cah-20260807.htm (published Aug 11, 2026)
- S22: 8-K filed Mar 23, 2026: Board Chair change. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000013/cah-20260317.htm (published Mar 23, 2026)
- S23: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/721371/000072137126000018/cah-20260331.htm (published Apr 30, 2026)
